LLY is trading at 2.6% up now at $1054.43 after receiving fresh bullish analyst commentary regarding its highly valued obesity franchise.
- Bank of America reiterated a Buy rating, though it made a modest trim to its price target (from $1,286 to $1,268).
- Analysts emphasize that the growth potential of Lilly’s obesity drug pipeline and the upcoming oral GLP-1 pill, orforglipron, remain underappreciated.
- Detailed reports highlight Phase 3 retatrutide data, orforglipron FDA timing, and manufacturing expansion as key 2026 growth drivers.